SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Benjamin Franklin Synthetic CCD

PatientBenjamin Franklin
Date of birth1950-01-17
IdentifiersMRN HR-EN004-SYN; SSN (made up) 000-04-3318
Document date2026-11-01
AuthorLydia Penhallow, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

Primary care visit for recurrent gout flares and painful, interrupted urination with blood in the urine. Concerns: Painful, interrupted urination and blood in the urine after car journeys; Gout flares keep confining him to his chair, and he does not want to give up wine and good dinners entirely. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Hydrochlorothiazide 25 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2019-05-06 to 2026-03-02stoppedS
Losartan 50 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-03-02activeS
Allopurinol 100 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-03-02 to 2026-03-30completedS
Allopurinol 100 mg oral tablet, two tablets (200 mg) by mouth dailyTwo tablets by mouth dailyOral route2026-03-30 to 2026-05-18completedS
Allopurinol 300 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-05-18activeS
Colchicine 0.6 mg oral tablet, one tablet by mouth daily for flare prophylaxisOne tablet by mouth dailyOral route2026-03-02 to 2026-09-14completedS
Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for pain, no more than 3 g a dayTwo tablets every 6 hours as needed; maximum 6 tablets a dayOral route2026-03-02activeS
Tamsulosin 0.4 mg oral capsule, one capsule by mouth at bedtime until surgeryOne capsule by mouth at bedtimeOral route2026-03-30 to 2026-04-20completedS
Atorvastatin 20 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-03-30activeS
Potassium citrate 10 mEq extended-release tablet, one tablet by mouth twice daily with mealsOne tablet by mouth twice daily with mealsOral route2026-05-18activeS
Prednisone 20 mg oral tablet, two tablets (40 mg) by mouth each morning for 5 daysTwo tablets by mouth each morning for 5 days, with foodOral route2026-07-06 to 2026-07-10completedS

Procedures

ProcedureDatesStatusEvidence
Non-contrast low-dose CT of the abdomen and pelvis: single 2.6 cm bladder stone of about 420 Hounsfield units, suggesting uric acid; no kidney or ureteric stones; no hydronephrosis; enlarged prostate2026-03-02 to 2026-03-02completedS
12-lead electrocardiogram: sinus rhythm, no left ventricular hypertrophy2026-03-02 to 2026-03-02completedS
Uroflowmetry: maximum flow 8.5 mL/s with a voided volume of 210 mL2026-03-30 to 2026-03-30completedS
Bladder ultrasound for post-void residual: 160 mL2026-03-30 to 2026-03-30completedS
Office flexible cystoscopy: single large bladder stone, trabeculated bladder, obstructing enlarged prostate with a median lobe, no bladder tumor2026-03-30 to 2026-03-30completedS
Transurethral laser cystolitholapaxy; stone analysis 100 percent uric acid2026-04-20 to 2026-04-20completedS
Transurethral resection of the prostate at the same operation; pathology benign prostatic hyperplasia2026-04-20 to 2026-04-20completedS
Arthrocentesis of the left knee: 25 mL of cloudy yellow fluid; needle-shaped, negatively birefringent crystals; Gram stain negative; culture later showed no growth2026-07-06 to 2026-07-06completedS

Immunizations

DateVaccineStatusEvidence
2025-10-08High-dose influenza vaccine, 2025-2026 seasoncompletedS
2023-11-06Pneumococcal conjugate vaccine PCV20completedS
2022-04-11Recombinant zoster vaccine, two-dose series completedcompletedS
2018-09-17Tdap vaccinecompletedS
2026-10-19High-dose influenza vaccine, 2026-2027 seasoncompletedS
2026-10-19Respiratory syncytial virus vaccine, single dosecompletedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
1724Occupational exposure to heated type metal as a compositor in London, with an obscure pain in the bones of the hand; he stopped heating the typeD (CLM-0002)
February 1727 (1726/7 Old Style)Pleurisy that very nearly carried him offD (CLM-0010)
1735Severe pleurisy ending in an abscess of the left lung, with full recoveryD (CLM-0011)
October 22, 1780Gout attack at midnight, recorded in his Dialogue between Franklin and the GoutD (CLM-0005)
Winter of 1780 to 1781Long and severe fit of gout through the winter, leaving him weakenedD (CLM-0006)
About 1781First symptoms of the calculous complaint (bladder stone)D (CLM-0007)

Family History

RelativeConditionAge at deathEvidence
fatherDied in 1744 at 89; no illness before his last; cause not recorded in the cited source89D (CLM-0012)
motherDied in 1752 at 85; no illness before her last; cause not recorded in the cited source85D (CLM-0012)
natural sonDied in 1736 at four of smallpox4D (CLM-0013)

Health Concerns

ConcernStatusEvidence
Painful, interrupted urination and blood in the urine after car journeysactiveS
Gout flares keep confining him to his chair, and he does not want to give up wine and good dinners entirelyactiveS

Assessment

Most recent measures: Urate [Mass/volume] in Serum or Plasma 5.9 on 2026-07-06; Sodium [Moles/volume] in Serum or Plasma 139 on 2026-09-14; Potassium [Moles/volume] in Serum or Plasma 4.7 on 2026-07-06; Carbon dioxide, total [Moles/volume] in Serum or Plasma 26 on 2026-09-14; Urea nitrogen [Mass/volume] in Serum or Plasma 21 on 2026-09-14; Creatinine [Mass/volume] in Serum or Plasma 1.33 on 2026-07-06; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 55 on 2026-07-06; Glucose [Mass/volume] in Serum or Plasma 104 on 2026-07-06; Calcium [Mass/volume] in Serum or Plasma 9.5 on 2026-03-02; Phosphate [Mass/volume] in Serum or Plasma 3.4 on 2026-03-02; Parathyrin.intact [Mass/volume] in Serum or Plasma 52 on 2026-03-02; 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 34 on 2026-03-02; Hemoglobin [Mass/volume] in Blood 14.2 on 2026-03-02; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 24 on 2026-03-02; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 128 on 2026-03-02; Hemoglobin A1c/Hemoglobin.total in Blood 5.6 on 2026-03-02; Albumin/Creatinine [Mass Ratio] in Urine 18 on 2026-03-02; pH of Urine 6.3 on 2026-09-14; Erythrocytes [#/area] in Urine sediment by Microscopy high power field 1 on 2026-05-18; Lead [Mass/volume] in Blood 3.1 on 2026-03-02; International Prostate Symptom Score [IPSS] 5 on 2026-09-14; Kidney failure 2-year risk [Likelihood] by KFRE 0.2 on 2026-03-02; Kidney failure 5-year risk [Likelihood] by KFRE 0.6 on 2026-03-02; US Urinary bladder Volume post void 30 on 2026-09-14; Maximum Urine flow by Uroflowmetry 8.5 on 2026-03-30; Volume of 24 hour Urine 1.45 on 2026-05-18; Urate [Mass/time] in 24 hour Urine 840 on 2026-05-18; Citrate [Mass/time] in 24 hour Urine 410 on 2026-05-18; Calcium [Mass/time] in 24 hour Urine 180 on 2026-05-18; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-10-19; Total score [Mini-Cog] 5 on 2026-10-19; Total score [AUDIT-C] 4 on 2026-10-19 [S]

Strengths and supports: Supports: family nearby, a wide circle of friends and correspondents, and a regular chess partner [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Gout with recurrent flares, mostly in the right big toe, without tophi; synthetic modern diagnosis linked to his documented goutactiveconfirmed M1A.0710S — Synthetic modern diagnosis; his recurrent gout is documented in his own letters (D).
Bladder stone (2.6 cm, uric acid on analysis) with bladder outlet obstruction, removed by cystolitholapaxy; synthetic modern diagnosis linked to his documented stoneresolvedconfirmed N21.0S — Synthetic modern diagnosis confirmed by CT and cystoscopy; his stone is documented in his own letters (D), though its composition is not known.
Chronic kidney disease stage G3a A1activeconfirmed N18.31S — Synthetic diagnosis; no measure of kidney function from his lifetime exists.
Essential hypertensionactiveconfirmed I10S — Synthetic diagnosis; no blood pressure from his lifetime exists.
Benign prostatic hyperplasia with lower urinary tract symptoms and bladder outlet obstruction, treated by transurethral resectionactiveconfirmed N40.1S — Synthetic diagnosis made at the urology consultation as the probable cause of the bladder stone; the cause of his historical stone is not documented.
Acute gout flare of the left knee, crystal-proven, during urate-lowering titration; resolvedresolvedconfirmed M10.062S — Synthetic flare at an unscheduled visit; flares are common in the first months of urate-lowering therapy. It does not echo a dated historical attack.

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-03-02Urate [Mass/volume] in Serum or Plasma9.1mg/dL3.5-7.2 mg/dLHighS
2026-03-02Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
2026-03-02Potassium [Moles/volume] in Serum or Plasma4.1mmol/L3.5-5.1 mmol/LNormalS
2026-03-02Carbon dioxide, total [Moles/volume] in Serum or Plasma25mmol/L22-29 mmol/LNormalS
2026-03-02Urea nitrogen [Mass/volume] in Serum or Plasma22mg/dL8-23 mg/dLNormalS
2026-03-02Creatinine [Mass/volume] in Serum or Plasma1.36mg/dL0.74-1.35 mg/dLHighS
2026-03-02Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M54mL/min/{1.73_m2}>=60 mL/min/1.73 m²LowS
2026-03-02Glucose [Mass/volume] in Serum or Plasma98mg/dL70-99 mg/dLNormalS
2026-03-02Calcium [Mass/volume] in Serum or Plasma9.5mg/dL8.6-10.3 mg/dLNormalS
2026-03-02Phosphate [Mass/volume] in Serum or Plasma3.4mg/dL2.5-4.5 mg/dLNormalS
2026-03-02Parathyrin.intact [Mass/volume] in Serum or Plasma52pg/mL15-65 pg/mLNormalS
2026-03-0225-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma34ng/mL30-100 ng/mLNormalS
2026-03-02Hemoglobin [Mass/volume] in Blood14.2g/dL13.2-16.6 g/dLNormalS
2026-03-02Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L7-55 U/LNormalS
2026-03-02Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation128mg/dL<=99 mg/dLHighS
2026-03-02Hemoglobin A1c/Hemoglobin.total in Blood5.6%<=5.6%NormalS
2026-03-02Albumin/Creatinine [Mass Ratio] in Urine18mg/g<=30 mg/gNormalS
2026-03-02pH of Urine5.2[pH]4.5-8 [pH]NormalS
2026-03-02Erythrocytes [#/area] in Urine sediment by Microscopy high power field12/[HPF]<=2 /[HPF]HighS
2026-03-02Lead [Mass/volume] in Blood3.1ug/dL<=3.5 ug/dLNormalS
2026-03-02International Prostate Symptom Score [IPSS]16{score}S
2026-03-02Kidney failure 2-year risk [Likelihood] by KFRE0.2%S
2026-03-02Kidney failure 5-year risk [Likelihood] by KFRE0.6%S
2026-03-30Urate [Mass/volume] in Serum or Plasma7.6mg/dL3.5-7.2 mg/dLHighS
2026-03-30Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-03-30Potassium [Moles/volume] in Serum or Plasma4.4mmol/L3.5-5.1 mmol/LNormalS
2026-03-30Carbon dioxide, total [Moles/volume] in Serum or Plasma24mmol/L22-29 mmol/LNormalS
2026-03-30Urea nitrogen [Mass/volume] in Serum or Plasma21mg/dL8-23 mg/dLNormalS
2026-03-30Creatinine [Mass/volume] in Serum or Plasma1.34mg/dL0.74-1.35 mg/dLNormalS
2026-03-30Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M55mL/min/{1.73_m2}>=60 mL/min/1.73 m²LowS
2026-03-30Glucose [Mass/volume] in Serum or Plasma96mg/dL70-99 mg/dLNormalS
2026-03-30US Urinary bladder Volume post void160mL<=100 mLHighS
2026-03-30Maximum Urine flow by Uroflowmetry8.5mL/s>=10 mL/sLowS
2026-03-30International Prostate Symptom Score [IPSS]16{score}S
2026-05-18Urate [Mass/volume] in Serum or Plasma6.4mg/dL3.5-7.2 mg/dLNormalS
2026-05-18Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
2026-05-18Potassium [Moles/volume] in Serum or Plasma4.5mmol/L3.5-5.1 mmol/LNormalS
2026-05-18Carbon dioxide, total [Moles/volume] in Serum or Plasma23mmol/L22-29 mmol/LNormalS
2026-05-18Urea nitrogen [Mass/volume] in Serum or Plasma20mg/dL8-23 mg/dLNormalS
2026-05-18Creatinine [Mass/volume] in Serum or Plasma1.31mg/dL0.74-1.35 mg/dLNormalS
2026-05-18Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M56mL/min/{1.73_m2}>=60 mL/min/1.73 m²LowS
2026-05-18Glucose [Mass/volume] in Serum or Plasma95mg/dL70-99 mg/dLNormalS
2026-05-18pH of Urine5.3[pH]4.5-8 [pH]NormalS
2026-05-18Erythrocytes [#/area] in Urine sediment by Microscopy high power field1/[HPF]<=2 /[HPF]NormalS
2026-05-18Volume of 24 hour Urine1.45L/(24.h)At least 2.5 L a day for stone preventionLowS
2026-05-18Urate [Mass/time] in 24 hour Urine840mg/(24.h)<=800 mg/(24.h)HighS
2026-05-18Citrate [Mass/time] in 24 hour Urine410mg/(24.h)>=320 mg/(24.h)NormalS
2026-05-18Calcium [Mass/time] in 24 hour Urine180mg/(24.h)<=250 mg/(24.h)NormalS
2026-05-18US Urinary bladder Volume post void35mL<=100 mLNormalS
2026-05-18International Prostate Symptom Score [IPSS]6{score}S
2026-09-14Urate [Mass/volume] in Serum or Plasma5.4mg/dL3.5-7.2 mg/dLNormalS
2026-09-14Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-09-14Potassium [Moles/volume] in Serum or Plasma4.6mmol/L3.5-5.1 mmol/LNormalS
2026-09-14Carbon dioxide, total [Moles/volume] in Serum or Plasma26mmol/L22-29 mmol/LNormalS
2026-09-14Urea nitrogen [Mass/volume] in Serum or Plasma21mg/dL8-23 mg/dLNormalS
2026-09-14Creatinine [Mass/volume] in Serum or Plasma1.32mg/dL0.74-1.35 mg/dLNormalS
2026-09-14Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M56mL/min/{1.73_m2}>=60 mL/min/1.73 m²LowS
2026-09-14Glucose [Mass/volume] in Serum or Plasma97mg/dL70-99 mg/dLNormalS
2026-09-14pH of Urine6.3[pH]4.5-8 [pH]NormalS
2026-09-14US Urinary bladder Volume post void30mL<=100 mLNormalS
2026-09-14International Prostate Symptom Score [IPSS]5{score}S
2026-07-06Urate [Mass/volume] in Serum or Plasma5.9mg/dL3.5-7.2 mg/dLNormalS
2026-07-06Potassium [Moles/volume] in Serum or Plasma4.7mmol/L3.5-5.1 mmol/LNormalS
2026-07-06Creatinine [Mass/volume] in Serum or Plasma1.33mg/dL0.74-1.35 mg/dLNormalS
2026-07-06Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M55mL/min/{1.73_m2}>=60 mL/min/1.73 m²LowS
2026-07-06Glucose [Mass/volume] in Serum or Plasma104mg/dL70-99 mg/dLHighS
2026-10-19Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
2026-10-19Total score [Mini-Cog]5{score}S
2026-10-19Total score [AUDIT-C]4{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
2026-03-02Body height175cmS
2026-03-02Body weight96kgS
2026-03-02Body mass index (BMI) [Ratio]31.3kg/m2S
2026-03-02Systolic blood pressure148mm[Hg]S
2026-03-02Diastolic blood pressure86mm[Hg]S
2026-03-02Heart rate74/minS
2026-03-02Respiratory rate16/minS
2026-03-02Body temperature36.7CelS
2026-03-02Oxygen saturation in Arterial blood by Pulse oximetry97%S
2026-03-30Body height175cmS
2026-03-30Body weight95.4kgS
2026-03-30Body mass index (BMI) [Ratio]31.2kg/m2S
2026-03-30Systolic blood pressure138mm[Hg]S
2026-03-30Diastolic blood pressure80mm[Hg]S
2026-03-30Heart rate70/minS
2026-03-30Respiratory rate16/minS
2026-03-30Body temperature36.6CelS
2026-03-30Oxygen saturation in Arterial blood by Pulse oximetry97%S
2026-05-18Body height175cmS
2026-05-18Body weight94.6kgS
2026-05-18Body mass index (BMI) [Ratio]30.9kg/m2S
2026-05-18Systolic blood pressure132mm[Hg]S
2026-05-18Diastolic blood pressure78mm[Hg]S
2026-05-18Heart rate72/minS
2026-05-18Respiratory rate16/minS
2026-05-18Body temperature36.7CelS
2026-05-18Oxygen saturation in Arterial blood by Pulse oximetry97%S
2026-09-14Body height175cmS
2026-09-14Body weight93.2kgS
2026-09-14Body mass index (BMI) [Ratio]30.4kg/m2S
2026-09-14Systolic blood pressure128mm[Hg]S
2026-09-14Diastolic blood pressure76mm[Hg]S
2026-09-14Heart rate68/minS
2026-09-14Respiratory rate14/minS
2026-09-14Body temperature36.6CelS
2026-09-14Oxygen saturation in Arterial blood by Pulse oximetry97%S
2026-07-06Body height175cmS
2026-07-06Body weight94kgS
2026-07-06Body mass index (BMI) [Ratio]30.7kg/m2S
2026-07-06Systolic blood pressure136mm[Hg]S
2026-07-06Diastolic blood pressure80mm[Hg]S
2026-07-06Heart rate84/minS
2026-07-06Respiratory rate16/minS
2026-07-06Body temperature37.7CelS
2026-07-06Oxygen saturation in Arterial blood by Pulse oximetry97%S
2026-10-19Body height175cmS
2026-10-19Body weight93kgS
2026-10-19Body mass index (BMI) [Ratio]30.4kg/m2S
2026-10-19Systolic blood pressure126mm[Hg]S
2026-10-19Diastolic blood pressure74mm[Hg]S
2026-10-19Heart rate66/minS
2026-10-19Respiratory rate14/minS
2026-10-19Body temperature36.6CelS
2026-10-19Oxygen saturation in Arterial blood by Pulse oximetry97%S

Encounters

DatePurposeStatusProvenance
2026-03-02Primary care visit for recurrent gout flares and painful, interrupted urination with blood in the urinefinishedS
2026-03-30Four-week gout and blood pressure review, with urology consultation for a bladder stonefinishedS
2026-05-18Review four weeks after stone removal and prostate resection, with urate titration and stone metabolic evaluationfinishedS
2026-09-14Gout, stone prevention, kidney, and blood pressure review at about six monthsfinishedS
2026-07-06Same-day sick visit for a hot, swollen left kneefinishedS
2026-10-19Subsequent annual wellness visitfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Start allopurinol 100 mg daily and raise it by 100 mg every 2 to 5 weeks until serum urate is below 6 mg/dL; HLA-B*58:01 testing is not indicated, because he is not of Southeast Asian or African ancestrycompletedGL-ACR-GOUT-2020S
Colchicine 0.6 mg daily for three to six months as flare prophylaxis; treat flares with a short prednisone course or extra colchicine, and avoid NSAIDs because of chronic kidney diseasecompletedGL-ACR-GOUT-2020, GL-CMID-2026S
Replace hydrochlorothiazide with losartan, which lowers blood pressure and slightly lowers urate; check potassium and creatinine 2 to 4 weeks after startingcompletedGL-ACR-GOUT-2020, GL-CMID-2026, GL-ACC-HTN-2017S
Urology referral to confirm and remove the bladder stone, look for bladder outlet obstruction and other causes of hematuria, and advise on stone preventioncompletedGL-AUA-STONE, GL-EAU-UROLITH, GL-AUA-BPHS
Uric acid stone prevention: fluids for a urine output of at least 2.5 L a day, potassium citrate to a urine pH of 6.0 to 6.5, stone analysis, and a 24-hour urine collectioncompletedGL-AUA-STONE, GL-EAU-UROLITHS
CMID kidney and blood pressure monitoring: blood pressure every visit; eGFR and urine albumin yearly at G3a A1; calcium, phosphate, and PTH at baseline; hemoglobin and the kidney failure risk equation yearly; statin for age over 50 with eGFR below 60; medication review for NSAIDs every visitcompletedGL-CMID-2026, GL-KDIGO-CKD-2024S
Limit alcohol, especially beer and spirits, and purine-rich meat, organ meat, and shellfish; avoid sugar-sweetened drinks; aim for gradual weight loss and daily walkingcompletedGL-ACR-GOUT-2020S

Goals

GoalTargetStatusOutcomeProvenance
Serum urate below 6 mg/dL on allopurinol by the six-month review2026-09-14completedSerum urate 5.4 mg/dL on allopurinol 300 mgS
Bladder stone removed and comfortable voiding with a normal post-void residual2026-05-18completedStone removed; IPSS from 16 to 6; residual 35 mLS
No gout flare for six months after starting urate-lowering therapy2026-09-14activeNot met: one knee flare in July while urate was still above target; none sinceS
Blood pressure below 130/80 without dizziness2026-09-14completed128/76 mmHg on losartanS
Urine output of at least 2.5 L a day and urine pH of 6.0 to 6.52026-09-14activeUrine pH 6.3 on potassium citrate; home measuring jug shows about 2.3 L a dayS

Functional Status

Mental Status